Opevesostat

Opevesostat is an orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), that is the first rate-liming step in steroid hormone biosynthesis. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include ODM‑208, MK‑5684, 4H-Pyran-4-one, 2-[(1 and 3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]-. Its PubChem CID is 135151902.

CAS No 2231294-96-3
Molecular Formula C21H26N2O5S
Molecular Weight 418.5 g/mol
Synonyms 2-(1,3-dihydroisoindol-2-ylmethyl)-5-[(1-methylsulfonylpiperidin-4-yl)methoxy]pyran-4-one

Frequently Asked Questions